Skip to main content
Premium Trial:

Request an Annual Quote

The Mouse Version

Some cancer patients are paying for their own mouse avatars on which to test possible drug therapies, the Associated Press reports.

"What I'm doing is personalized cancer treatment. It's the wave of the future," breast cancer patient Eileen Youtie tells the AP. "Part of this is trying to eliminate chemos that are not going to work on me. I don't want to waste time taking them and poison my body."

By grafting a portion of their tumor into lab mice, patients like Youtie hope to learn what drugs will best target their particular cancer. For some patients, the AP notes that mouse avatar testing can reveal that a tumor appears to be sensitive to a drug that isn't typically used to treat that cancer type.

Still, the AP notes that such testing is experimental and may not provide more information than gene tests or better outcomes than standard therapies. Mouse avatar testing, it adds, can cost upwards of $10,000 and isn't typically covered by insurance.

"I do see promise, but it's very time-consuming, it's very expensive," says Oklahoma Medical Research Foundation's Alana Welm. "For the average patient, standard care is going to be the way to go."

 

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.